Parnax Lab growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024FY23Mar 2023FY21 and earlierAlpha Plus
−5.7%−0.4%+4.5%
FY21 and earlierEvery year the company has filed comes with Alpha Plus.
−41.5%+34.2%+15.0%
−42.9%+36.4%+13.7%
−23.9%+45.9%+70.3%
+11.1%+4.1%−9.2%
+234.4%+129.6%+21.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PARNAXLAB₹109.47

Parnax Lab Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Revenue Growth—+4.5-0.4-5.7
EBITDA Growth—+15.0+34.2-41.5
EBIT Growth—+13.7+36.4-42.9
EPS Growth—+70.3+45.9-23.9
Total Assets Growth—-9.2+4.1+11.1
Cash from Operations Growth—+21.8+129.6+234.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.